{'fraction_non_alphanumeric': 0.052732502396931925, 'fraction_numerical': 0.03547459252157239, 'mean_word_length': 5.177514792899408, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Follow‐up study of thymomas with special reference to their clinical stages

Follow‐up data were obtained for 96 cases of thymoma. The one‐year survival rate was 84.3%, the three‐year 77.1%, the five‐year 74.1%, and the ten‐year 57.1%. The five‐year survival rate of total resection group was 88.9%; that of non‐radically treated group was 44.4%. Clinical stages were defined: Stage I—macroscopically encapsulated and microscopically no capsular invasion; Stage II—1. macroscopic invasion into surrounding fatty tissue or mediastinal pleura, or 2. microscopic invasion into capsule; Stage III—macroscopic invasion into neighboring organ; Stage IVa—pleural or pericardial dissemination; Stage IVb—lymphogenous or hematogenous metastasis. Five‐year survival rates of each clinical stage were 92.6% in Stage I, 85.7% in Stage II, 69.6% in Stage III, and 50% in Stage IV. Recurrence after total resection was found in six of 69 cases. Seven of 13 patients treated by subtotal resection survived more than five years with postopertive radiotherapy.